EHA 2026 Had Something for Everyone, From Pediatric Practitioners to “Myeloma Maniacs”

Why It Matters

These breakthroughs could dramatically improve survival and quality of life for myeloma patients and children with high‑risk ALL, while genomic insights promise earlier detection and tailored interventions for pediatric cancer predisposition.

Key Takeaways

• Talquetamab + daratumumab ± pomalidomide cuts myeloma progression risk 70%+
• Two‑year PFS reaches 81% with talquetamab triplet, far above standard
• Blinatumomab replaces chemo in high‑risk B‑ALL, raising EFS to 83%
• NGS reveals pediatric cancer predisposition genes, prompting new surveillance guidelines

Pulse Analysis

The MonumenTAL‑3 phase‑3 trial marks a watershed moment for relapsed/refractory multiple myeloma. By pairing the GPRC5D‑directed antibody talquetamab with daratumumab—optionally adding pomalidomide—researchers achieved a 72% reduction in progression or death and an 81% two‑year progression‑free survival, far surpassing the daratumumab‑pomalidomide‑dexamethasone backbone. These results not only validate GPRC5D as a potent therapeutic target but also suggest a shift toward antibody‑centric regimens that may reduce reliance on traditional chemotherapy and its associated toxicities.

Pediatric oncology also saw a paradigm shift as the AIEOP‑BFM ALL 2017 trial replaced two intensive chemotherapy blocks with blinatumomab, a bispecific T‑cell engager. The strategy lifted event‑free survival to 83% versus 70% with standard chemotherapy, slashed central‑nervous‑system relapses, and cut post‑transplant mortality. By minimizing cytotoxic exposure, the approach promises better long‑term health outcomes for children, aligning with a broader movement toward immunotherapy‑driven, less invasive treatment protocols in high‑risk leukemia.

Beyond immediate therapeutic advances, the congress underscored the growing influence of next‑generation sequencing on pediatric cancer care. Comprehensive genomic profiling is uncovering germline predisposition variants that were previously invisible, prompting the development of surveillance guidelines for syndromes such as Li‑Fraumeni. Early detection through systematic imaging and laboratory monitoring can improve survival, while the identification of actionable mutations opens avenues for targeted immunotherapies and even prophylactic vaccines. As sequencing becomes routine, clinicians will increasingly integrate genetic risk assessment into personalized treatment pathways, reshaping the future landscape of childhood cancer management.